anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Atrial fibrillation (AF) is prevalent among patients with end-stage kidney disease (ESKD) undergoing dialysis, and both conditions are associated with a heightened risk of cardiovascular diseases. Anticoagulation is essential for preventing thromboembolic complications in these patients. This study aimed to evaluate the effects of factor Xa inhibitors compared to vitamin K antagonists (VKAs) for AF patients on dialysis.
METHODS: A comprehensive search of PubMed and Embase databases was conducted to identify relevant studies published up to June 2024. Eligible studies compared factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) with VKAs in AF patients on dialysis, with primary outcomes of stroke or systemic embolism(SSE) and major bleeding.
RESULTS: A total of 7 studies (3 randomized controlled trials and 4 observational cohorts) were included. For the RCTs, the use of factor Xa inhibitors was associated with a reduced risk of SSE compared to VKAs (odds ratio [OR] = 0.37, 95% confidence interval [CI]:0.15-0.93). There was no significant difference in the risk of major bleeding events between the two groups (OR = 0.65, 95%CI:0.32-1.33). Observational cohort studies yielded similar results with a decreased risk of SSE (hazard ratio [HR] = 0.74, 95%CI:0.57-0.96) and no significant difference in major bleeding (HR = 0.87, 95%CI:0.62-1.22). No differences in treatment effect between apixaban and rivaroxaban were observed for efficacy (p-interaction = 0.44) and safety (p-interaction = 0.21) outcomes.
CONCLUSION: Factor Xa inhibitors, particularly apixaban and rivaroxaban, were associated with a lower risk of SEE without an increase in major bleeding, which might be convenient alternatives to VKAs in managing AF in patients with ESKD on dialysis.
PURPOSE:To directly build a dentine layer and an enamel layer on an artificial tooth frame by forming an opaque calcining and forming material obtained by hardening a mixture of opaque calcined and crushed grains and an opaque liquid to easily formable hardness by photopolymerization on a support base tooth model, and also, hardening it by photopolymerization, and moreover, drawing it out of the support base tooth model, and thereafter, burning it. CONSTITUTION:By mixing opaque burned and crushed grains 2 and an opaque liquid 4 and radiating ultraviolet rays for 3-15 seconds, an opaque burning and forming material 9 semi- hardened to easily forming hardness is made. By containing the opaque burning and forming material 9 in an opaque container 10, an opaque material 1 contained in a container is formed. Subsequently, the opaque burning and forming material 9 is taken out of the container 10, formed to roughly uniform thickness on a support base model M and an opaque layer 12 is formed. The opaque layer 12 is hardened completely by radiating ultraviolet rays about 60-120 seconds, thereafter, drawn out, calcined at 980 deg.C by using an electric furnace 14, and an artificial tooth frame secondary mold 15 is formed. As for the secondary mold 15, by bringing it to uniform thickness working and making the lower end thin, an artificial tooth frame F is formed. The artificial tooth frame F is returned to the support base tooth model M, and a dentine layer D and an enamel layer E are formed.
A high percentage of patients with acute coronary syndrome develop heart failure due to the ischemic event. Regulatory T (Treg) cells are lymphocytes with suppressive capacity that control the immune response and include the conventional CD4+ CD25hi Foxp3+ cells and the CD4+ CD25var CD69+ LAP+ Foxp3- IL-10+ cells. No human follow-up studies focus on Treg cells' behavior after infarction and their possible relationship with ventricular function as a sign of postischemic cardiac remodeling. This study aimed to analyze, by flow cytometry, the circulating levels of CD69+ Treg cells and CD4+ CD25hi Foxp3+ cells, their IL-10+ production as well as their function in patients with acute myocardial infarction (AMI), and its possible relation with ventricular dysfunction. We found a significant difference in the percentage of CD4+ CD25hi Foxp3+ cells and IL-10+ MFI in patients with AMI at 72 hours compared with the healthy control group, and the levels of these cells were reduced 6 months post-AMI. Regarding the suppressive function of CD4+ CD25+ regulatory cells, they were dysfunctional at 3 and 6 months post-AMI. The frequency of CD69+ Treg cells was similar between patients with AMI at 72 hours postinfarction and the control groups. Moreover, the frequency of CD69+ Treg cells at 3 and 6 months postischemic event did not vary over time. Treg cells play a role in regulating inflammation after an AMI, and its function may be compromised in this pathology. This work is the first report to evaluate CD69+ Foxp3- Treg cells in AMI patients.
The time a patient and family caregiver (FCG) spend together in a patient's final days is filled with emotion. Patients may turn inward and be filled with peace, or they may be bothered by symptoms. Caregivers often experience feelings of helplessness and anticipatory grief. Learning and providing a skill such as Reiki may give caregivers a way to help the patient with symptoms while at the same time feeling useful. Patient and caregiver closeness may be enhanced. Reiki has been shown to be helpful with symptoms such as pain, anxiety, depression, fatigue, and others. However, teaching caregivers of terminal hospice patients, Reiki has not been studied. The knowledge gained from this feasibility study will guide future interventions aimed at the comfort of hospice patients and FCGs.

Approximately 1.49 million Medicare beneficiaries received hospice care during 2017, and most had a FCG. During the final days or weeks, FCGs are unsure of what do or how to best help the patient when everyday caregiving actives such as physical care or nutrition are not required or no longer desired by the patient. Caregiver symptoms of depression, anxiety, or anticipatory grief increase toward the end of life along with increased patient symptoms. Having a specific skill to help the patient with symptoms or simply to show care and provide touch may empower FCGs and improve the quality of life for both caregivers and patients.
Randomized subjects to the text reminder group will be asked about their intention to undergo CRC screening in the next 6 months. For those who are at pre-contemplation and contemplation stage, a standard text message will be delivered to invite them to undergo CRC screening by informing them that they are due to CRC screening because they are aged \>50 years and are yet to receive CRC screening. No HBM-based health education video or personalized risk assessment will be provided. The chatbot then asks the subject's intention to undergo CRC screening again. For those who propelled to preparation stage or those who are at preparation stage at the beginning, the website link of the government-subsidized CRC screening program which lists the names of all primary care physicians and their contact and co-payment information will be provided.
For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
Hemi-face injected with PRFM. PRFM was produced from 9 mL of blood (Healeon Medical, Inc).
Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of one or more transcription factors that cooperate with NF-AT family proteins to regulate expression of a Th2-associated cytokine gene are disclosed. In one embodiment, the activity of a maf family protein (e.g., c-Maf or a small maf protein, such as p18) is modulated. In another embodiment, the activity of a protein that interacts with an NF-AT family protein (e.g., NIP45) is modulated. Combination methods, for example wherein the activities of a maf family protein and an NF-AT protein are modulated or the activities of a maf protein and an NF-AT-interacting protein are modulated, are also encompassed by the invention. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed. NIP45 compositions, including isolated nucleic acid molecules encoding NIP45, antisense nucleic acid molecules, recombinant expression vectors containing a NIP45 nucleic acid molecule, host cells into which such expression vectors have been introduced and non-human transgenic animals carrying a NIP45 transgene, are also provided by the invention. The invention further provides isolated NIP45 proteins and peptides, NIP45 fusion proteins and anti-NIP45 antibodies. Methods of using the NIP45 compositions of the invention are also disclosed.
A powder injection of benzimidazole hydrochloride antiparasitic is characterized in that: when using, hydrochloric acid albendazole sulfoxide or other hydrochloride benzimidazole drugs is dissolved or dispersed by solvent, and then injects the solution. Preferably, the solvent for melting the hydrochloride albendazole sulfoxide is water or water/1, 2-propanediol or 1, 2-propanediol/formal glycerine; and the proper dissolvent for melting hydrochloride oxfendazole is 1, 2-propanediol or 1, 2-propanediol/formal glycerine. The powder injection can be used for preparing high concentration drug solution and is better than water injection having been sold in market, therefore, it is fit for preventing parasitosis. The injection can be conveniently transported and stored, and the administration manner (e.g. drench or injection) and concentration of the injection can be regulated according to different use. The injection can combine with macrolide drug and/or levamisole hydrochloride to form compound injection, administrated by injection or oral.
BACKGROUND: Obesity is an increasing problem, even in young women of reproductive age. Obesity has a negative impact on conception, the course of pregnancy, and neonatal outcomes. Caring for obese pregnant women has becoming an important aspect of standard prenatal care. The Guideline "Obesity and Pregnancy" of the German Society of Gynecology and Obstetrics aims to create evidence-based recommendations which can be used to improve the care of obese pregnant women. As obesity is a worldwide problem, many societies for obstetrics and gynecology have created national guidelines.
METHODS: We reviewed the following guidelines for obesity and pregnancy: American College of Obstetricians and Gynecologists (ACOG) 2021, Royal College of Obstetrics and Gynecology (RCOG) 2018; AND Society of Obstetricians and Gynecologists of Canada (SOGC) 2019. These guidelines were compared to the German guideline.
RESULTS: There are some variations between the guidelines, though no major contradictions exist. Disparities were found regarding the recommendations for substitution of high folic acid and Vitamin D. Furthermore, the recommended time for screening for gestational diabetes and the methods to control fetal growth differ between the guidelines. Regarding place of birth, RCOG allows delivery in midwifery-led units in the absence of other high-risk circumstances, while others request facility of care by neonatologists and medical staff trained in care of obese women. Induction of labor at term due to increased risk of intrauterine demise is mostly limited to women with a body mass index of 40 kg/m2. Only one guideline considers induction of all obese women. For intrapartum management, the majority allows tolerating of longer labor times to delivery if fetal monitoring is sufficient and fetal stress is excluded. Special encouragement of breastfeeding and healthy lifestyle is commonly recommended; only in the Canadian guideline, postpartum depression evaluation is requested due to the overall high prevalence of depression and anxiety in obese women.
CONCLUSION: All guidelines consider pregnancies in obese women as high-risk pregnancies and emphasize the need for preconception counseling. There are special needs in pregnancy care and in the intrapartum and postpartum management to be observed.
Our previous study reckons that the impact of the rs1801133 variant of 5,10-methylenetetrahydrofolate reductase (MTHFR) on coronary artery disease (CAD) is possibly mediated by cardiometabolic disorder. This study is performed to verify this hypothesis. Four hundred and thirty CAD patients and 216 CAD-free individuals were enrolled in this case-control study. The rs1801133 variant was genotyped by PCR-RFLP. Severity of coronary lesions was evaluated by number of stenotic coronary vessels and extent of coronary stenosis. The rs1801133 T allele significantly increased homocysteine levels in patients with CAD and CAD-free individuals. Individuals with the T allele of rs1801133 had an increased risk of developing CAD. In contrast, individuals with the TT genotype of rs1801133 were at high risk of multiple vessel lesions. The carriers of CT genotype had higher levels of systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), and high-sensitivity C-reactive protein (hs-CRP), and lower levels of apolipoprotein A1 (APOA1) than those with CC genotype in male patients with CAD. The receiver operating characteristic (ROC) curve and precision-recall (PR) curve indicated that hyperhomocysteinemia was sensitive to predict the severity of CAD. Multivariate logistic regression revealed that homocysteine, rs1801133, age, smoking, weight, body mass index (BMI), lipoprotein(a) [Lp(a)], and hs-CRP were independent risk factors for CAD. The increased risk of CAD and severity of coronary lesions associated with rs1801133 in the Chinese Han population were attributed, at least partly, to high homocysteine levels. Hyperhomocysteinemia had a high predictive value for severe CAD or multiple vessel lesions.
Metastasis initiates when cancer cells escape from the primary tumor, which requires changes to intercellular junctions. Claudins are transmembrane proteins that form the tight junction, and their expression is reduced in aggressive breast tumors. However, claudins' roles during breast cancer metastasis remain unclear. We used gain- and loss-of-function genetics in organoids isolated from murine breast cancer models to establish that Cldn7 suppresses invasion and metastasis. Transcriptomic analysis revealed that Cldn7 knockdown induced smooth muscle actin (SMA)-related genes and a broader mesenchymal phenotype. We validated our results in human cell lines, fresh human tumor tissue, bulk RNA-seq, and public single-cell RNA-seq data. We consistently observed an inverse relationship between Cldn7 expression and expression of SMA-related genes. Furthermore, knockdown and overexpression of SMA-related genes demonstrated that they promote breast cancer invasion. Our data reveal that Cldn7 suppresses breast cancer invasion and metastasis through negative regulation of SMA-related and mesenchymal gene expression.
CAPRELSA can prolong the QT interval. Torsades de pointes and sudden death have occurred in patients receiving CAPRELSA. Do not use CAPRELSA in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Correct hypocalcemia, hypokalemia and/or hypomagnesemia prior to CAPRELSA administration. Monitor electrolytes periodically. Avoid drugs known to prolong the QT interval. Only prescribers and pharmacies certified with the restricted distribution program are able to prescribe and dispense CAPRELSA [see Warnings and Precautions (5.1, 5.16)].
FIELD: medicine; pharmaceuticals.SUBSTANCE: present invention provides a method for preparing a pharmaceutical composition which is a tablet and contains a crystalline form of the tofogliflozin monohydrate as an active ingredient. Method involves mixing an auxiliary substance and a tofogliflozin monohydrate for preparing a powdered mixture and preparing the tablet from the powder mixture by direct pressing. Adjuvant contains filler, a disintegrating agent and a sliding agent. Crystalline form of tofogliflozin monohydrate includes crystalline form I, crystalline form II or mixture thereof. Composition practically does not contain calcium silicate. Preferably, the pharmaceutical composition, which is a tablet obtained using the described method, includes lactose hydrate, crystalline cellulose, sodium croscarmellose and hydrogenated oil and/or magnesium stearate as auxiliary components.EFFECT: tofogliflozin monohydrate tablet obtained by direct pressing is characterized by improved disintegration and solubility properties.10 cl, 4 dwg, 17 tbl, 12 ex
PROBLEM TO BE SOLVED: To obtain an antipyretic high in safety and little in side effects by including the extract of Nandina domestica as an active ingredient. SOLUTION: The antipyretic contains the extract of the fruits and leaves of Nandina domestica as an active ingredient. The antipyretic preferably further contains acetaminophen or ibuprofen. The extract of the Nandina domestica is preferably obtained by extracting the fruits of the Nandina domestica with water, hot water or an organic solvent such as ethanol by a conventional method. The Nandina domestica extract (converted into the raw galenical) and acetaminophen are preferably compounded in a weight ratio of 500:1 to 1:100, and the Nandina domestica extract and the ibuprofen are also preferably compounded in a weight ratio of 5000:1 to 1:60.  The antipyretic is administered at a daily dose of 1-10 g (converted into the raw galenical) for an adult, when containing the Nandina domestica extract alone as the active ingredient, at a total daily dose of 1.15-11 g, when containing the Nandina domestica and the acetaminophen, or at a total daily dose of 1.15-10.6 g, when containing the Nandina domestica and the ibuprofen.
The invention relates to a metformin hydrochloride sustained-release tablet and a preparing method and application thereof. The metformin hydrochloride sustained-release tablet is composed of a tablet core medicated layer, a tablet core boosting layer and a coating layer. The tablet core medicated layer is composed of metformin hydrochloride, a sustained-release agent, a bonding agent and a lubricating agent. The tablet core boosting layer is composed of hydroxypropyl methyl cellulose, povidone K30, polyoxyethylene and a lubricating agent. The coating layer is composed of cellulose acetate, polyethylene glycol 400 and ethanol. The sustained-release agent is a montmorillonite composite modified by the polyethylene glycol 400. According to the metformin hydrochloride sustained-release tablet and the preparing method and application, the montmorillonite composite made by modifying montmorillonite through the polyethylene glycol 400 serves as a sustained-release material, and the application of releasing the metformin hydrochloride slowly through creative excipient selection and an optimized excipient proportion. The invention further provides the application of the metformin hydrochloride sustained-release tablet in preparing of medicine for treating diabetes mellitus.
Children assigned to this arm will brush/clean teeth with Livionex Dental Gel twice a day for up to 12 months.They will undergo a dental exam by a trained dentist including caries assessment (at baseline, 1, 3, 6, 9 or 12 months), dental plaque photograph, (at baseline, 1, 3, 6 and 9 or 12 months), and swab samples for dental plaque and saliva will be collected at all study visits. A questionnaire will be given to address dentifrice and brushing experience. Data on compliance and side-effects of toothpastes will be collected at each of the calls.
BackgroundRadiation therapy is an important component of treatment for breast cancer, especially in the setting of breast conservation. Even though cancer patients who are receiving radiation treatments follow established hygiene and skin-care protocols they still experience differing degrees of cutaneous skin reactions and associated symptoms of dryness, itchiness, burning sensations, and pain.1-7 For some patients the side-effects associated with radiation therapy can become so severe serious consideration is given to discontinuing treatments. The treatments currently used for reducing cutaneous reactions and symptoms are very limited and often ineffective.5-7 Anti-inflammatories and steroid-based topical pharmaceutical agents are used sparingly due in part to research findings8 and potential harmful side-effects.7 This has left physicians and patients using a trial and error approach in seeking an alternative treatment that will help these patients cope with (and sometimes endure) the cutaneous radiation side-effects. Ongoing clinical experience and discussions with present and former radiation patients reveals that skin irritation, breakdown, pain and associated suffering are common side-effects that patients wish they did not have to experience. The lack of effective, efficient, non-pharmacological treatments for reducing symptoms associated with cutaneous skin reactions to radiation cancer therapy is problematic. Study Objectives the overall aim of the study is to determine if biologically active A. barbadensis is a therapeutic agent for reduction of cutaneous side effects women experience as a result of undergoing radiation therapy for breast cancer.The primary aim is to determine if there is a significant reduction or increase of cutaneous skin reactions using A. barbadensis on the irradiated skin of the breast or chest wall in comparison to following the standard CCI non-pharmacological treatment protocol and in comparison to using the moist inert vehicle gel on the irradiated site.The secondary aim is to explore if there is a reduction or increase in subjective symptoms at the irradiated site with the use of A. barbadensis in comparison to following the standard CCI 'best care' non-pharmacological treatment protocol and in comparison to using the moist inert vehicle gel on the irradiated site.MethodThis study is a single blind randomized controlled trial using a three Arm design. Analysis stratification is being conducted according to radiation technique, breast size, smoker vs. non-smoker, nutrition, protocol adherence, and prior chemotherapy. The control arm will treat the skin reaction as per standard CCI breast radiation protocol